U.S. markets closed
  • S&P 500

    4,662.85
    +3.82 (+0.08%)
     
  • Dow 30

    35,911.81
    -201.79 (-0.56%)
     
  • Nasdaq

    14,893.75
    +86.95 (+0.59%)
     
  • Russell 2000

    2,162.46
    +3.02 (+0.14%)
     
  • Crude Oil

    83.90
    +0.08 (+0.10%)
     
  • Gold

    1,821.30
    +4.80 (+0.26%)
     
  • Silver

    23.07
    +0.15 (+0.66%)
     
  • EUR/USD

    1.1427
    +0.0012 (+0.10%)
     
  • 10-Yr Bond

    1.7720
    +0.0610 (+3.57%)
     
  • GBP/USD

    1.3685
    +0.0006 (+0.04%)
     
  • USD/JPY

    114.4800
    +0.2800 (+0.25%)
     
  • BTC-USD

    42,862.73
    -308.36 (-0.71%)
     
  • CMC Crypto 200

    1,030.63
    +4.90 (+0.48%)
     
  • FTSE 100

    7,592.56
    +49.61 (+0.66%)
     
  • Nikkei 225

    28,333.52
    +209.24 (+0.74%)
     

A Year After First Covid-19 Vaccine, It’s Crunchtime for Moderna and Pfizer

·9 min read
A Year After First Covid-19 Vaccine, It’s Crunchtime for Moderna and Pfizer
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

Moderna has climbed 66% in the year since the first Covid-19 shot, while Pfizer has risen 22% and BioNTech has surged 136%.